GeoVax expects to begin before the end of the year. disseminated to users of Standard and Poor 's Advisor Insight. is made available to the broadest possible investor base. systemic reactions in the majority of trial participants . ( white blood cell ) and antibody responses. were similar for the 1 / 10th and full dose. primes at eliciting T cell responses .